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Accumulation of vascular smooth muscle cells (VSMC) in response to inﬂammatory stimuli is a key event
in atherogenesis, which commonly occurs in sinuous vessels with turbulent blood ﬂow what leads to
hemolysis and consequent free heme accumulation, a known pro-oxidant and pro-inﬂammatory
molecule.
In this work, we investigated the effects of free heme on VSMC, and the molecular mechanisms
underlying this process.
Free heme induces a concentration-dependent migration and proliferation of VSMC which depends on
the production of reactive oxygen species (ROS) derived from NADPH oxidase (NADPHox) activity.
Additionally, heme activates redox-sensitive proliferation-related signaling routes, such as Mitogen
Activated Protein Kinase (MAPK) and NF-kB, and induces Heme Oxygenase-1 (HO-1) expression.
NADPHox-dependent proliferative effect of heme seems to be endogenously modulated by HO since the
pretreatment of VSMC with HO inhibitors potentiates heme-induced proliferation and, in parallel,
increases ROS production. These effects were no longer observed in the presence of heme metabolites,
carbon monoxide and biliverdin.
The data indicate that VSMC proliferation induced by heme is endogenously modulated by a critical
counter-regulatory crosstalk between NADPHox and HO systems.
 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Cardiovascular diseases represent the major cause of mortality
and morbidity in western countries. Among these conditions,
atherosclerosis is the most prominent one. The ﬁrst step in
atherogenesis is the vascular inﬂammation, which is characterized
by oxidized LDL inﬁltration and foam cell formation. This process is
accompanied by endothelial cell lesion, extracellular matrix expo-
sure, platelets aggregation, adhesion of leukocytes and, mainly, by
vascular smooth muscle cell (VSMC) accumulation [1]. The VSMC
dysfunction is characterized by an exacerbation of cell migration
and proliferation, events which are ampliﬁed through the release of
inﬂammatory mediators [2e4]. VSMC dysfunction has beenologia, Instituto de Biologia,
tembro 87 fds, Rio de Janeiro,
algo).
der the Elsevier OA license.implicated in the pathogenesis not only of atherosclerosis, but also
of other cardiovascular pathological situations, such as restenosis.
The exacerbated activation of VSMC is a key event in the ﬁbrous cap
formation (atherosclerosis) or in the neointima formation (reste-
nosis). Notably, these cardiovascular diseases occur mainly in
sinuous vessels, and are associated with turbulent blood ﬂow,
which may lead to hemolysis and consequent release of free heme
[5]. Importantly, our group, and others, has characterized heme as
a strong pro-inﬂammatory molecule to neutrophils, macrophages
an endothelium, inwhichmost effects aremediated by ROS derived
from NADPHox complex activation [6e10].
The oxidative stress that leads to an increasedROSproductionvia
NADPHox activation has been implicated in many cardiovascular
disorders [11]. The production of ROS is positively regulated by
many of the cytokines whose expression is increased after vascular
injury, and also by oscillatory shear stress and mechanical disrup-
tion [12]. On the otherhand, lowlevels of ROShavebeen shown tobe
necessary for the activation of redox-sensitive signaling pathways
that inﬂuence many physiological processes [13].
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also able to induce the HO system, which is responsible for its
metabolization into carbon monoxide (CO), iron and biliverdin,
which can be converted to bilirubin by biliverdin reductase. This
system is comprised of the constitutive isoform, HO-2, and by the
inducible isoform, HO-1 [14]. HO-2 constitutively metabolizes
endogenous heme and evidences have shown that its deletion
increases ROS accumulation [15]. HO-1 is a stress-responsive
enzyme, whose induction by free heme and other stimuli, such as
pro-inﬂammatory molecules, increases the rate of heme catabo-
lism. The by-products of HO-1emediated heme catabolism have
established antioxidant and anti-inﬂammatory properties [16].
In this scenario, free heme emerges as a putative molecule able
to activate key molecular mechanisms in vascular cells that
contribute to several cardiovascular disorders. In this work we
aimed to elucidate how the pro-and antioxidant properties of heme
could modulate VSMC migration and proliferation and the mech-
anisms underlying its effects.
2. Methods
2.1. Cell culture
A7r5 vascular smooth muscle cells obtained of rat thoracic aorta
were originally from the American Type Culture Collection (Rock-
ville, MD USA). Cell culture is better explained in Supplementary
methods.
2.2. Cell migration
Chemotaxis assay was accomplished in a modiﬁed Boyden
Chamber after 4 h of migration. This assay is better described in
Supplementary methods.
2.3. Cell proliferation
Cell proliferation was measured by Thymidine [H3] incorpora-
tion after 48 h of treatment. This assay is better described in
Supplementary methods.
2.4. ROS production
ROS production was measured using the DHR and DCF probes.
Intracellular DHR oxidation was examined under an Olympus IX71
inverted microscope (Tokyo, Japan) equipped for epiﬂuorescence
and DCF oxidation was monitored in the Victor3 Mutilabel ﬂuo-
rescent plate reader (PerkinElmer, Waltham, MA USA). ROS assays
are better described in Supplementary Methods.
2.5. Western blot analysis
Total protein content in the cell extracts was determined by the
BCA method, except on immunopreciptates samples. Samples were
submitted to electrophoresis and transfered to PVDF membranes.
Immunoreactive proteins were visualized by the ECL detection.
Western blotting is better described in Supplementary methods.
2.6. Statistical analysis
Statistical signiﬁcance was assessed by one-way ANOVA, fol-
lowed by Bonferroni’s t-test, and P < 0.05 was taken as statistically
signiﬁcant. ROS assay (CM-H2-DCFDA) was analyzed by two-way
ANOVA, followed by t-student test in each point.3. Results
3.1. Heme induces VSMC migration and proliferation via NADPHox
Firstly we investigated heme effects on the two main VSMC
functions usually altered in cardiovascular diseases: migration and
proliferation. As can be observed in Fig. 1, heme has a potent
chemotactic activity on VSMC (Fig. 1A), and is also a potent inducer
of VSMC proliferation (Fig. 1B). For both cell functions the effect of
heme peaked at 10 mM, a concentration that is believed to be
reached in regions of turbulent blood ﬂow, and can be found in the
plasma of patients during hemolytic episodes such as such as
severe hemolytic crisis in sickle cell disease (up to 20 mM heme) or
thalassemia (50e280 mM heme) [10,17]. Heme has shown effects
similar to Ang II, used as positive control [18] for migration, but was
more potent than this prototypical vasoactive agent in inducing
VSMC proliferation. Heme effects were shown to be redox-
sensitive, since the antioxidant Trolox (100 mM) abrogated
heme-induced VSMC migration and proliferation (Fig. 1C,D).
Accordingly, Fig. 2A shows that heme (10 mM) induces a strong
ROS production after 1 h of incubation with VSMC. Corroborating
recent studies that showed heme as an inductor of ROS generation
via NADPHox in neutrophils, macrophages and in VSMC [7,8,19], the
pretreatment of cells with DPI (10 mM), a NADPHox inhibitor [20],
prevented heme-induced ROS production in A7r5 VSMC (Fig. 2A).
Moreover, DPI strongly inhibited heme-induced VSMC migration
(Fig. 2B) and blunted the proliferative capability of heme-treated
VSMC that reached levels below the controls. (Fig. 2C), indicating
that heme effects on VSMC migration and proliferation are modu-
lated by NADPHox.
3.2. Heme activates redox-sensitive signaling pathways
Among the redox-sensitive molecules, ERK-2, a member of
MAPK family, is of crucial importance to VSMC proliferation and
migration [21]. In VSMC pretreated with the ERK-2 inhibitor
PD98059 (10 mM), migration induced by heme was partially
inhibited (Fig. 3A) and heme proliferative effect on VSMC was
impaired (Fig. 3B). Supporting the data, heme induced ERK-2
phosphorylation in VSMC (Fig. 3C), an effect that was inhibited in
cells pretreated with DPI (Fig. 3C).
NF-kB is another redox-sensitive pathway and a possible target
of ERK-2 pathway [22]. NF-kB activation can be evaluated by its
translocation to nucleus, where this factor promotes gene tran-
scription. The heme effect on NF-kB activation was detected 1 h
after VSMC stimulation and, similar to ERK-2 phosphorylation, was
strongly inhibited by DPI, as evaluated by immunocytochemistry
and western blotting (Suppl. Fig. 1). This effect is ERK/MAPK
dependent, once PD98059 inhibited the nuclear translocation of
NF-kB induced by heme (Suppl. Fig. 1A). The data suggest that
NADPHox activation by heme mediates the activation of redox-
sensitive signaling pathways involved in VSMC migration and
proliferation.
3.3. Heme oxygenase activity down-modulates the heme effect
Heme is endogenously metabolized by HO system, generating
carbon monoxide (CO), iron and biliverdin, which can be converted
to bilirubin under catalytic activity of biliverdin reductase. In VSMC
challenged with heme for 24 h there was no change in the
expression of constitutive HO-2. On the other hand, heme induced
HO-1 expression in VSMC (Suppl. Fig. 2). Corroborating this data,
we observed that hemewas able to induce HO-1 mRNA expression;
however heme did not affect NOX4 mRNA expression (one of the
major NADPHox expressed in VSMC; Suppl. Fig. 3). We discarded
Fig. 1. VSMC migration and proliferation induced by heme are redox-dependent. (A) Migration of VSMC toward indicated concentrations of heme (3e30 mM) or Ang II (100 nM) in
a Boyden chamber after 4 h incubation. (B) Proliferation of VSMC treated with heme (3e30 mM) or Ang II (100 nM) for 48 h at 37 C, determined by thymidine incorporation assay.
(C-D) VSMC were pretreated with Trolox (100 mM) and stimulated with heme (10 mM) for migration (C) or proliferation (D). Angiotensin II (Ang II) was used as positive control for
migration and proliferation. Results are show as fold of increase in relation to cells treated with medium alone (control). The results are representative from three to ﬁve different
experiments. Data are means  SD (*p < 0.05 versus control; #p < 0.05 versus heme).
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on VSMC proliferation (data not shown).
In order to investigate the role of HO system on heme effects,
VSMC were treated with the HO pan inhibitor, tin protoporphyrin
IX (SnPP 3 mM) or with the selective HO-1 inhibitor, zincFig. 2. Inhibition of NADPH oxidase activity impairs heme effects on VSMC. (A) Heme-indu
the absence or in the presence of a NADPHox inhibitor DPI (10 mM). ROS production was asse
Methods. The results are representative from four experiments. (B) Inhibition of NADPHox b
allowed to migrate to heme (10 mM) for 4 h at 37 C in a Boyden chamber. (C) Inhibition of NA
without heme (10 mM) for 48 h at 37 C and when indicated were pretreated with DPI. Cell p
as fold of increase in relation to cells treated with medium alone (control). Data are meansprotoporphyrin IX (ZnPP 10 mM). Fig. 4 shows that the inhibition of
HO activity by both, SnPP (Fig. 4A) or ZnPP (Fig. 4B), potentiates the
effect of heme on VSMC proliferation. Additionally, it was observed
that inhibition of HO-1 by ZnPP induced a further increase in heme-
induced ROS production (Fig. 4C), suggesting that activation of HOced ROS production by VSMC: Cells were incubated with or heme (10 mM/1 h/37 C) in
ssed by imunoﬂuorescence using dihydrorhodamine 123 (DHR) as probe as described in
y DPI prevents heme-induced cell migration: VSMC pretreated with DPI (10 mM) were
DPHox by DPI prevents heme-induced cell proliferation: VSMC were incubated with or
roliferation was determined using the thymidine incorporation assay. Results are show
 SD (*p < 0.05 versus control; #p < 0.05 versus heme).
Fig. 3. Heme activates redox-sensitive signaling pathways. Inhibition of ERK activation by PD98059 (10 mM) inhibits the effect of heme (10 mM) on (A) migration and (B) prolif-
eration of VSMC. Results are show as fold of increase in relation to cells treated with medium alone (control). Data are means  SD (*p < 0.05 versus untreated group; #p < 0.05
versus heme). (C) Heme induced ERK phosphorylation is dependent on NADPHox activation: Cultured VSMC treated with heme (10 mM) for indicated times at 37 C in the presence
or not of DPI (10 mM). Whole-cell lysates were immunoblotted with anti-ERK polyclonal (upper inset) and with anti-ERK-2 polyclonal antibody (lower inset).
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induced by heme.
3.4. Heme metabolites counter-regulate the heme effect
To investigate a possible counter-regulatory effect of HO
metabolites on heme-induced proliferation, VSMC were treated
with biliverdin (10 mM), bilirubin (10 mM) and/or with the CO donor,
CO-RM (10 mM) (Fig. 5A). The metabolites had no effect on the basal
neither in heme-induced VSMC proliferation. However, the
potentiating effect of HO inhibitor on heme-induced proliferation
was impaired when the VSMC were treated with hememetabolites
(Fig. 5A). Furthermore, when both systems, NADPHox and HO, were
blocked, the heme effect on VSMC proliferation was abrogated
(Fig. 5B). The same was observed when the cells were treated with
the antioxidant Trolox and SnPP (Fig. 5B), suggesting that the by-
products of both systems may act together tomodulate heme effect
on VSMC.
4. Discussion
In some regions of the vasculature, the increase of the blood
turbulence promotes the destruction of fragile or old red blood cells
within the vascular compartment, allowing hemoglobin to escape
to plasma. Although hemoglobin rapidly binds to serum proteins
like haptoglobin, during extensive hemolysis the amount of cell-
free hemoglobin exceeds the binding capacities of those
hemoglobin-scavenging mechanisms, resulting in intravascular
free heme release and accumulation [2].
It has beenwell demonstrated that heme acts as a double-edged
sword. In physiological conditions, as a prostetic group ofhemoproteins, heme is critically important for various biological
processes. However, the free heme, released from hemoproteins by
oxidative stimuli is pro-oxidant and enhances oxidative stress and
inﬂammation [6,23]. Recent studies have shown that free heme
acts as a danger signal which can induce pro-inﬂammatory proteins
expression, ROS generation and the activation of redox-sensitive
molecules in cultured cardiac resident cells [24]. ROS produced in
the vasculature contribute to the pathogenesis of cardiovascular
conditions, and a critical source of ROS is the vascular NADPHox.
The upregulation of this enzyme brings about the oxidative stress
underlying atherosclerosis and NADPHox activity has been high-
lighted as a potential target for pharmacological interventions in
cardiovascular diseases [9,25]. Furthermore, evidences have shown
that heme is a potent inductor of LDL oxidation [26] and may
contribute to atherogenesis.
It is well known that heme is able to induce NADPHox in
different cell types, such as neutrophil, macrophage and endo-
thelium [6e10,14]. In this work we demonstrate that heme
directly activates VSMC, promoting cell proliferation and migra-
tion, suggesting a key role of this molecule in vascular dysfunction
observed during hemolytic episodes. These effects are dependent
on its ability to promote ROS production through the activation of
the NADPHox system. Heme-induced ROS generation triggers
redox-sensitive signaling pathways, such as ERK-2 and NF-kB,
which are involved in VSMC proliferation. We also investigated
a possible heme effect on others MAPK and we observed that
heme had no effect on p38 and JNK phosphorylation (data not
shown).
On the other hand, heme is known as the main inductor of HO-1
system, which acts as potent antioxidant, protecting the vascula-
ture, mainly attenuating the inﬂammatory response in the vessel
Fig. 4. Inhibitors of HO potentiate heme proliferative effect on VSMC. VSMC were incubated with heme (10 mM) for 48 h at 37 C and when indicated were pretreated with (A) SnPP
(3 mM) or (B) ZnPP (10 mM). Cell proliferation was determined using the thymidine incorporation assay. (C) HO inhibitors enhance ROS production induced by heme in VSMC: VSMC
probed with CM-H2-DCFDA were incubated for 180 min/37 C with heme (10 mM) in the presence or not of ZnPP (10 mM) and/or DPI (10 mM). ROS production along the time was
detected by ﬂuorescence as described in Methods. The results are representative of three to ﬁve independent experiments. Data are means  SD (t-student test in each point:
*p < 0.05 versus control; #p < 0.05 versus heme. Two-way anova: $p < 0.05 versus control).
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olism can be toxic at very high concentrations, recent evidence
indicates that they are not toxic at physiological concentrations in
normal cells, and may have important anti-oxidant and anti-Fig. 5. The proliferative effect of heme on VSMC is modulated by NADPHox and HO activiti
with a carbon monoxide-releasing molecule (CO: 10 mM) alone, or with biliverdin (BV: 10 mM
incubation with heme (10 mM) for 48 h at 37 C; and (B) Effect of both HO and NADPHox
(10 mM) for 48 h at 37 C and when indicated were pretreated with SnPP (3 mM), DPI (10
experiments. Data are means  SD (*p < 0.05 versus control; #p < 0.05 versus heme; &p <inﬂammatory properties [16]. Supporting this idea, our data
suggest that the induction of HO-1 by hemewould be a key factor in
the cell defense mechanism against the oxidative processes trig-
gered by the activation of NADPHox induced by heme itself.es. (A) Effect of HO metabolites on heme-induced proliferation: VSMC were pretreated
) and bilirubin (BR: 10 mM), or in the presence of SnPP (3 mM), or medium alone before
inhibition on heme-induced proliferation. Cultured VSMC were incubated with heme
mM) or Trolox (100 mM). The results are representative of three to ﬁve independent
0.05 versus heme þ SnPP).
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induces HO-1, without affecting the HO-2 expression. The inhibi-
tion of HO activity with a pan-inhibitor SnPP, or with ZnPP, an HO-
1 selective inhibitor, potentiates the proliferative effect of heme on
VSMC. This effect seems to be a consequence of an increase in
heme bioavailability (Suppl. Fig. 4), which leads to increased ROS
production, and an impairment in the generation of HO-derived
antioxidant products. Accordingly, as shown in Fig. 5, the addi-
tion of CO/biliverdin and bilirubin impairs the potentiation of HO
inhibitor on heme proliferative effect. Those heme metabolites,
due to their antioxidant properties [28], are described to inhibit
MAPK pathway in VSMC [19,29,30], which confers an important
anti-proliferative role for these molecules. Furthermore, heme
metabolites [30,31] were described to induce cell cycle arrest in
G0 phase. Corroborating the data, we have also observed that
when NADPHox activity was inhibited, heme induces cell cycle
arrest in G0 phase, probably via heme metabolites. On the other
hand, the inhibition of HO accelerates G2 phase induction by
heme, indicating an anti-proliferative effect of HO by-products
(Suppl. Fig. 5). These results were conﬁrmed by MTT assay,
showing that the proliferative effect of heme on VSMC was
potentiated by HO inhibition and prevented in the presence of
a NADPHox inhibitor (Suppl. Fig. 6).
A balance between the activity of NADPHox and HO systems
modulating different cell functions has been frequently reported.
HO-1 induction has potent protective actions against ROS-induced
oxidative damage both in vitro and in vivo [27,32]. A recent report
has demonstrated a link between ROS-generated from NADPHox
and HO-1 activation during mesenteric arteries remodeling [33].
Additionally, Bellner & colleagues [15] observed that HO-2 deletion
induced NADPHox activation, ROS increase and NF-kB activation in
endothelial cells.
Interestingly, in our experimental model, heme (10 mM) effect
on NADPHox overcomes HO system activity, culminating on VSMC
proliferation. Our data contrast with others by Chang and
colleagues demonstrating that the treatment of VSMCwith heme at
5 mM for 7e21 days inhibited proliferation, via HO-1 [34]. On the
same direction, Hyvelin et al., showed in vivo that HO-1 induced by
heme (30 uM e plasma concentration), prevented the in-stent
stenosis in rat or rabbit after 28 days [35]. So, it is conceivable to
assume that the prolonged treatment with heme promotes a long
lasting upregulation of HO system, which overcomes NADPHox
activation, leading to inhibition of VSMC proliferation. Additionally,
the short half-life of heme (Suppl. Fig. 4) may explain the rapid
effect on NADPHox and the longtime of the anti-proliferative effect
by HO system (HO-1 and by heme metabolites).
It is well-established that HO system down-modulates VSMC
proliferation and that heme has pro-oxidant properties, however
we are now showing, consistently, for the ﬁrst time that the
treatment with heme triggers the VSMC proliferation, which is
dependent on ROS derived from the NADPHox activation and
associated to the activation of ROS-sensitive signaling pathways.
Moreover, we show that the proliferative effect on VSMC activated
via the pro-oxidant properties of heme is endogenously regulated
through the balance between the activity of NADPHox complex and
HO system, particularly HO-1, which diminishes heme bioavail-
ability as well as generates antioxidant/anti-proliferative metabo-
lites (Suppl. Fig. 7). Thus, concomitantly, endogenous HO-derived
by-products are acting to minimize the pro-oxidant effect of
heme, and the inhibition of HO activity leads to a potentiation of
heme proliferative effect.
A better knowledge of the underlying mechanisms involved in
heme effects on NADPHox and HO systems may lead to the
development of new strategies for the treatment of vascular
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